Gilead, Parker Institute grab stakes in Penn immunotherapy spinout's $100 million round

Gilead Sciences Inc. took another step toward building out its immunotherapy program as part of a $100 million Series A financing for a Philadelphia company. The San Francisco-based Parker Institute for Cancer Immunotherapy, which has championed new research and alliances around ways to use the body's immune system to beat back cancer, also participated in the private stock sale for University of Pennsylvania spinout Tmunity Therapeutics Inc. Co-found ed in 2015 by Penn T-cell therapy pioneer Dr.…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news